Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe
The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.
Category: Hypersomnias
Hypersomnias
Latest
Hypersomnias
Latest
Alkermes Reports Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia
The REVITALYZ study met its primary endpoint, demonstrating significant improvements in excessive daytime sleepiness for adults with idiopathic hypersomnia treated with once-nightly LUMRYZ.
Hypersomnias
Latest
Why an Efficacious Drug Therapy for Narcolepsy Is Underused
Low prescribing rates persist even as evidence supports benefit, pointing to missed conversations, unclear expectations, and fragile early treatment periods.
Narcolepsy
Latest
Narcolepsy Patients Show Enhanced Brain Waste Clearance Through Compensatory Vasomotor Activity
New research reveals how orexin deficiency may paradoxically improve glymphatic function when NT1 patients are awake.
Idiopathic Hypersomnia
Latest
FDA Grants Orphan Drug Designation to IH Drug Contender
A phase 3 trial is underway to evaluate the drug's efficacy and safety in adults with IH, with enrollment expected to complete by the end of 2025.
Insufficient Sleep Syndrome
Latest
Sleep Disorders and Lack of Sleep Plague Active US Military Personnel
A new study found that 85% of active duty servicemen and servicewomen have sleep disorders.
Kleine-Levin Syndrome
Latest
Kleine-Levin Syndrome Foundation Taps First Executive Director
An experienced non-profit leader and author is appointed to the first-ever professional staff role for the foundation.